XTX Topco’s CytoMed Therapeutics GDTC Stock Holding History

XTX Topco’s Portfolio GDTC Stock Details GDTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,136	Closed	-$10.1K	–	4327
2026 Q1	$10.1K	Buy	+10,136	New	+$10.7K	﹤0.01%	3682

Other funds holding GDTC

AIM

Axiom Investment Management New York $150M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

XTX Topco's GDTC Position: Q2 2026 in Review

XTX Topco sold out of CytoMed Therapeutics (GDTC) in Q2 2026, closing a stake of 10,136 shares — an estimated $10.1K sold.

XTX Topco first reported a position in GDTC in Q1 2026 and held it in 1 quarter. The position peaked at $10.1K in Q1 2026. 3 funds tracked by Wall St. Rank hold GDTC as of Q2 2026.

XTX Topco reported no remaining CytoMed Therapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 10,136 CytoMed Therapeutics shares in Q2 2026, an estimated $10.1K.
XTX Topco first reported a position in CytoMed Therapeutics in Q1 2026 and held it in 1 quarter.
XTX Topco's CytoMed Therapeutics position peaked at $10.1K in Q1 2026.
3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.